Pelthos holders re-elect 8 directors, approve 2026 equity plan with 500,000-share reserve

Pelthos Therapeutics Inc.

Eight director nominees elected at the Sept 29, 2026 annual meeting; Matthew Pauls received the most withheld votes: 110,700 vs 2,775,221 for.
Grant Thornton LLP ratified as independent auditor for fiscal 2026: 3,394,740 votes for, 1 against and 1,353 abstaining.
2026 Equity Incentive Plan approved with 2,698,543 votes for, 187,365 against and 13 abstaining; it replaces the 2023 plan and reserves 500,000 shares plus a 5% annual evergreen increase.
Record date Aug 4, 2026: 3,828,469 common shares and 52,128 Series A preferred outstanding; 3,396,094 votes present (70.0%) constituted a quorum.
Non-employee director compensation capped at $750,000 per fiscal year ($1,000,000 in initial service year); forfeited shares can be reissued under the plan.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.